N/A N=4 Active Powered Prosthesis (APEX) for Spinal Cord Injury
Spinal Cord Injuries
Primary: User Ability to Operate the APEX Device — 4; 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=243 Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)
Atopic Dermatitis
Primary: Change From Baseline in Eczema Area and Severity Index (EASI) at Week 12 — -15.8; -15.8; -17.5; -13.1 score on a scale
Phase 2 N=331 A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Lymphoma
Primary: Phase Ib: Percentage of Participants With Adverse Events (AEs) — 100; 100; 100; 100 percentage of participants
Phase 2 N=43 Safety, Tolerability, and Efficacy of IONIS-GHR-LRx in Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands
Acromegaly
Primary: Percent Change in Serum Insulin-like Growth Factor-1 (IGF-1) From Baseline to 28 Days After Last Dose — 8.9; -2.8; -7.5 percent change — p=0.306
Phase 4 N=273 A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder
Anxiety Disorders,Generalized Anxiety Disorder
Primary: Change in Pediatric Anxiety Rating Scale (PARS) Severity Score — -6.38; -7.81 score on a scale — p=0.0281
N/A N=86 Evaluation of Daily Disposable Silicone Hydrogel Multifocal Toric Contact Lenses
Visual Acuity
Primary: Overall Vision — 58.37; 53.53 Units on a Scale
N/A N=158 Clinical Evaluation of an Investigational Lipid Drop in Non-contact Lens Wearing Patients
Visual Acuity
Primary: Change From Baseline Ocular Comfort (30-Day) — 21.4; 10.0 Units on a scale
N/A N=19 Improving Nutritional Choices in Adolescents
Overweight and Obesity
Primary: Visits to Fast Food Restaurants
Phase 2 N=13 Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Recurrent Plasma Cell Myeloma
Primary: Overall Response Percentage — 0.077 percentage of responders
Phase 2 N=18 Ipilimumab and Nivolumab in Leptomeningeal Metastases
Leptomeningeal Carcinomatosis
Primary: Percentage of Participants With Overall Survival — 44 percentage of participants
Phase 2 N=23 FX-322 in Sensorineural Hearing Loss
Sensorineural Hearing Loss
Primary: Number of Participants With Treatment-emergent Adverse Event(s) (TEAEs) — 2; 3; 5; 6 Participants
Phase 4 N=343 Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients
Type 1 Diabetes Mellitus
Primary: Percentage of Time of Glucose Concentration Within the Target Range of Greater Than or Equal to (>=) 70 to Less Than or Equal to (<=) 180 Milligrams Per Deciliter…
Phase 3 N=127 Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis
Juvenile Idiopahtic Arthritis
Primary: Number of Participants With Malignancy: All Periods of Parent and Extension Study — 1 Participants
N/A N=298 Prevena™ Incisional Negative Pressure Wound Therapy in Re-operative Colorectal Surgery
Surgical Site Infection
Primary: Occurrence of Superficial Surgical Site Infection — 11; 21; 107; 128 Participants
Phase 2 N=20 Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS
Multiple Sclerosis, Chronic Progressive
Primary: Number of Participants With Treatment-emergent Adverse Events — 18 Participants